期刊
DERMATOLOGIC CLINICS
卷 28, 期 2, 页码 371-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.det.2010.02.004
关键词
Recessive dystrophic epidermolysis bullosa; Bone marrow transplantation; Bone marrow stem cells; Stem cell microenvironment; Clinical trial
类别
资金
- NIGMS NIH HHS [T32 GM082771] Funding Source: Medline
Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited blistering disease caused by mutations in the type VII collagen gene, resulting in defective anchoring fibrils at the epidermal-dermal junction. At present, no curative treatment for RDEB exists. Mounting evidence on reprogramming of bone marrow stem cells into skin has prompted the authors and others to develop novel strategies for treatment of RDEB. The rationale for bone marrow stem cell therapies for RDEB is based on the evidence that bone marrow derived cells are guided into becoming skin cells, given the right microenvironment. Preclinical studies in mouse models have shown that wild-type bone marrow derived cells can ameliorate the phenotype of RDEB and improve survival by restoring the expression of type VII collagen and the anchoring fibrils. At present, several clinical studies are ongoing around the world to study the therapeutic effects of bone marrow stem cell transplantation for RDEB. These studies provide a framework for future development of standardized, effective methods for stem cell transplantation to cure severe inherited skin diseases, including RDEB.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据